Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update

Wednesday, May 11, 2011 General News
Email Print This Page Comment bookmark
Font : A-A+

Neuralstem, Inc.

Statements of Operations

Three Months

Ended March 31,

2011

2010

Revenues

$          -

$         -

Operating expenses:

Research and development costs

1,738,728

1,899,963

General and administrative expenses

1,772,482

1,687,835

Depreciation and amortization

25,293

29,063

Total operating expenses

3,536,503

3,616,861

Operating loss

(3,536,503)

(3,616,861)

Nonoperating income (expense):

Litigation settlement

250,000

-

Interest income

22,892

5,811

Interest expense

-

(659)

Warrant issuance and modification expense

-

(1,906,800)

Gain (loss) from change in fair value adjustment of warrant obligations

161,809

(1,248,452)

Total nonoperating income (expense)

434,701

(3,150,100)

Net loss attributable to common shareholders

$   (3,101,802)

$  (6,766,961)

Net loss per share - basic and diluted

$        (0.07)

$       (0.18)

Weighted average common shares outstanding - basic and diluted

47,692,878

38,539,226



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook